» Articles » PMID: 7382552

Nonalcoholic Steatohepatitis: Mayo Clinic Experiences with a Hitherto Unnamed Disease

Overview
Journal Mayo Clin Proc
Specialty General Medicine
Date 1980 Jul 1
PMID 7382552
Citations 794
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis is a poorly understood and hitherto unnamed liver disease that histologically mimics alcoholic hepatitis and that also may progress to cirrhosis. Described here are findings in 20 patients with nonalcoholic steatohepatitis of unknown cause. The biopsy specimens were characterized by the presence of striking fatty changes with evidence of lobular hepatitis, focal necroses with mixed inflammatory infiltrates, and, in most instances, Mallory bodies; Evidence of fibrosis was found in most specimens, and cirrhosis was diagnosed in biopsy tissue from three patients. The disease was more common in women. Most patients were moderately obese, and many had obesity-associated diseases, such as diabetes mellitus and cholelithiasis. Presence of hepatomegaly and mild abnormalities of liver function were common clinical findings. Currently, we know of no effective therapy.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


Weight-adjusted waist circumference index with hepatic steatosis and fibrosis in adult females: a cross-sectional, nationally representative study (NHANES 2017-2020).

Lian Y, Wang Y, Yang Y, Chen J BMC Gastroenterol. 2025; 25(1):137.

PMID: 40045243 PMC: 11884151. DOI: 10.1186/s12876-025-03706-4.


Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Jarmakiewicz-Czaja S, Sokal-Dembowska A, Filip R Medicina (Kaunas). 2025; 61(2).

PMID: 40005309 PMC: 11857189. DOI: 10.3390/medicina61020192.


Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.

Byrne C, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 39962331 DOI: 10.1038/s41575-025-01045-z.


Overexpression of Apolipoprotein A-I Alleviates Insulin Resistance in MASLD Mice Through the PPARα Pathway.

Wang Y, Zhang Y, Wang Y Int J Mol Sci. 2025; 26(3).

PMID: 39940822 PMC: 11817368. DOI: 10.3390/ijms26031051.